Indonesia Receives Sinopharm and Sinovac Vaccines; Here Are The Differences
Translator
Editor
30 April 2021 21:19 WIB
TEMPO.CO, Jakarta - The Food and Drug Monitoring Agency or BPOM had granted an emergency use authorization for COVID-19 vaccines Sinovac and Sinopharm produced by Chinese companies. Today afternoon, 482,400 doses of the Sinopharm vaccine landed in Indonesia.
While both COVID-19 vaccines were based on inactivated viruses, they are different from each other. The differences are as follows.
- Manufacturing company
Sinovac is developed by Sinovac Biotech Ltd, while Sinopharm is manufactured by the Beijing Biological Products Institute, a subsidiary of the China National Biotec Group (CNBG).
- Dosage and time interval between injections
Sinovac requires two doses, 14 days apart, for people aged 18-59 years old, while for the elderly, it is taken 28 days apart. Sinopharm also requires two doses but it is taken 21-28 days apart.
- Immunogenicity
The immunogenicity of the Sinopharm vaccine for adults reaches 99.92 percent within 14 days after the second injection, and 100 percent for the elderly. For the Sinovac vaccine, it is up to 99.23 percent within three months.
- Efficacy
The efficacy of the Sinovac vaccine is 65.3 percent, while the Sinopharm vaccine is 78 percent.
- Distributors
The Sinovac vaccine is distributed by state-run pharmacy Bio Farma, which also develops the vaccine's raw materials. Meanwhile, the Sinopharm vaccine is distributed by state-run pharmacy Kimia Farma.
- Usage
The Indonesian government procured the Sinovac vaccine for the national mass vaccination that is prioritized for health workers, the elderly, and public service employees. Meanwhile, the Sinopharm vaccine will be used for the "gotong royong" or private COVID-19 vaccination program.
Read: BPOM Grants Emergency Use for Sinopharm Vaccine
BISNIS | FRANCISCA CHRISTY